Latest news with #SumitomoDainipponPharmaCo
Business Insider
7 days ago
- Business
- Business Insider
Sumitomo Dainippon Pharma Co (DNPUF) Gets a Buy from Jefferies
Jefferies analyst Stephen Barker maintained a Buy rating on Sumitomo Dainippon Pharma Co on August 1 and set a price target of Yen1,600.00. The company's shares closed last Thursday at $7.24. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Barker covers the Healthcare sector, focusing on stocks such as Sumitomo Dainippon Pharma Co, Otsuka Holdings Co, and Eisai Co. According to TipRanks, Barker has an average return of 8.8% and a 51.35% success rate on recommended stocks. In addition to Jefferies, Sumitomo Dainippon Pharma Co also received a Buy from J.P. Morgan's Seiji Wakao in a report issued on July 30. However, on July 31, TR | OpenAI – 4o reiterated a Hold rating on Sumitomo Dainippon Pharma Co (Other OTC: DNPUF). Based on Sumitomo Dainippon Pharma Co's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $105.65 billion and a net profit of $2.42 billion. In comparison, last year the company earned a revenue of $79.53 billion and had a GAAP net loss of $197.26 billion
Business Insider
09-07-2025
- Business
- Business Insider
Jefferies Reaffirms Their Buy Rating on Sumitomo Dainippon Pharma Co (DNPUF)
In a report released today, Stephen Barker from Jefferies maintained a Buy rating on Sumitomo Dainippon Pharma Co, with a price target of Yen1,300.00. The company's shares closed yesterday at $6.34. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Barker is a 3-star analyst with an average return of 2.9% and a 47.06% success rate. Barker covers the Healthcare sector, focusing on stocks such as Sumitomo Dainippon Pharma Co, Astellas Pharma, and Asahi Intecc Co. The word on The Street in general, suggests a Hold analyst consensus rating for Sumitomo Dainippon Pharma Co with a $5.93 average price target.
Business Insider
28-06-2025
- Business
- Business Insider
Citi Reaffirms Their Sell Rating on Sumitomo Dainippon Pharma Co (DNPUF)
In a report released yesterday, Hidemaru Yamaguchi from Citi maintained a Sell rating on Sumitomo Dainippon Pharma Co (DNPUF – Research Report), with a price target of Yen800.00. The company's shares closed last Thursday at $6.55. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Yamaguchi covers the Healthcare sector, focusing on stocks such as Astellas Pharma, Chugai Pharmaceutical Co, and Sumitomo Dainippon Pharma Co. According to TipRanks, Yamaguchi has an average return of -2.6% and a 37.50% success rate on recommended stocks. Sumitomo Dainippon Pharma Co has an analyst consensus of Moderate Buy, with a price target consensus of $6.24. The company has a one-year high of $7.12 and a one-year low of $2.19. Currently, Sumitomo Dainippon Pharma Co has an average volume of 212.
